Zhejiang East-Asia Pharmaceutical Co Ltd
605177
Company Profile
Business description
Zhejiang East-Asia Pharmaceutical Co Ltd is mainly engaged in the production of bulk pharmaceutical chemicals, tablets, granules and capsules. The company's main products are: Ofloxacin, levofloxacin, loratadine hydrochloride, levofloxacin hydrochloride, trimebutine maleate, ketoconazole, terbinafine hydrochloride, piperazine, ticlazole and so on.
Contact
No. 118, Laodong North Road
23rd Floor, Chamber of Commerce Building
Huangyan District
Zhejiang Province
Taizhou
CHNT: +86 57689185675
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
1,749
Stocks News & Analysis
stocks
Chart of the Week: Opportunities with wide-moat retailers
Consumer defensive names look undervalued.
stocks
New ASX share added to our best ideas
Earnings outlook is strong and the shares trade at a discount to our fair value.
stocks
Fair value downgraded for ASX heavyweight
Our capital allocation rating was also lowered due to balance sheet weakness.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,233.40 | 35.70 | 0.39% |
| CAC 40 | 7,966.95 | 71.01 | 0.90% |
| DAX 40 | 24,113.62 | 232.90 | 0.98% |
| Dow JONES (US) | 46,441.10 | 43.21 | 0.09% |
| FTSE 100 | 9,446.43 | 96.00 | 1.03% |
| HKSE | 27,214.59 | 359.03 | 1.34% |
| NASDAQ | 22,755.16 | 95.15 | 0.42% |
| Nikkei 225 | 44,831.32 | 280.47 | 0.63% |
| NZX 50 Index | 13,441.79 | 7.80 | 0.06% |
| S&P 500 | 6,711.20 | 22.74 | 0.34% |
| S&P/ASX 200 | 8,939.90 | 34.10 | 0.38% |
| SSE Composite Index | 3,882.78 | 20.25 | 0.52% |